KNSA
HealthcareKiniksa Pharmaceuticals International, plc
$41.06
$-0.95 (-2.25%)
Jan 5, 2026
Price History (1Y)
Analysis
Kiniksa Pharmaceuticals International, plc is a healthcare company operating in the specialty and generic drug manufacturers sector. With a market capitalization of $3.11 billion, the company has significant scale. Additionally, Kiniksa employs 315 individuals, indicating a moderate size for its industry. The company's financial health appears strong, with gross margin at 52.8%, operating margin at 13.3%, and profit margin at 6.0%. Returns on equity (ROE) stand at 7.4%, while returns on assets (ROA) are 3.8%. The balance sheet is also healthy, with a debt to equity ratio of 1.81 and a current ratio of 3.85. Kiniksa's cash position is substantial, totaling $352.10 million, while its total debt amounts to just $9.72 million. Kiniksa's valuation context can be analyzed through various metrics. The company's price-to-earnings (P/E) ratio stands at 93.32 on a trailing twelve-month basis and 22.29 on a forward basis. Revenue growth has been significant, with a year-over-year increase of 61.2%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Visit website →Key Statistics
- Market Cap
- $3.11B
- P/E Ratio
- 93.32
- 52-Week High
- $44.42
- 52-Week Low
- $17.82
- Avg Volume
- 430.61K
- Beta
- 0.04
Company Info
- Exchange
- NMS
- Country
- United Kingdom
- Employees
- 315